Drug Profile
NVP 1102
Alternative Names: NVP-1102Latest Information Update: 03 Aug 2016
Price :
$50
*
At a glance
- Originator Navipharm
- Class Muscle relaxants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Spasm
Most Recent Events
- 31 Mar 2015 Launched for Spasm in South Korea (unspecified route)
- 30 Nov 2014 Phase-III clinical trials in Spasm in South Korea (unspecified route) prior to November 2014
- 30 Nov 2014 Preregistration for Spasm in South Korea (unspecified route)